Edition:
United Kingdom

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

8.79USD
13 Dec 2017
Change (% chg)

$0.48 (+5.78%)
Prev Close
$8.31
Open
$8.35
Day's High
$9.05
Day's Low
$8.35
Volume
29,617
Avg. Vol
7,778
52-wk High
$9.59
52-wk Low
$3.04

Chart for

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate,... (more)

Overall

Beta: 2.60
Market Cap(Mil.): $117.83
Shares Outstanding(Mil.): 12.64
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Galmed Pharmaceuticals Q3 loss per share $0.23

* Galmed Pharmaceuticals reports third quarter 2017 financial results and provides business update

09 Nov 2017

BRIEF-Galmed Pharmaceuticals announces ‍publication of a paper entitled "role of aramchol in steatohepatitis and fibrosis in mice"

* Galmed Pharmaceuticals Ltd - ‍publication of a paper entitled "role of aramchol in steatohepatitis and fibrosis in mice" in hepatology communications

05 Oct 2017

BRIEF-Galmed Pharmaceuticals announces pricing of offering to existing investors, members of board

* Galmed Pharmaceuticals announces pricing of offering of ordinary shares to existing investors and members of the board of directors

03 Aug 2017

BRIEF-Galmed Pharmaceuticals reports Q2 loss per share of $0.22

* Galmed Pharmaceuticals reports second quarter 2017 financial results and provides business update

31 Jul 2017

Earnings vs. Estimates